GAMMAGARD LIQUID is indicated as a therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

LIMITATIONS OF USE:  GAMMAGARD LIQUID has not been studied in immunoglobulin-naive patients with CIDP. GAMMAGARD LIQUID maintenance therapy in CIDP has not been studied for periods longer than 6 months. After responding during an initial treatment period, not all patients require indefinite maintenance therapy with GAMMAGARD LIQUID in order to remain free of CIDP symptoms. Individualize the duration of any treatment beyond 6 months based upon the patient’s response and demonstrated need for continued therapy.

Intended for US Healthcare Professionals only

    GAMMAGARD LIQUID

    Dosing & Infusion Rates for CIDP

    CIDP = chronic inflammatory demyelinating polyneuropathy.

    IVIG dose and infusion rates for CIDP1

    When starting a patient on treatment with GAMMAGARD LIQUID, the correct dose and rate of administration is based on the treatment indication and the individual patient’s weight. 

    GAMMAGARD LIQUID is administered intravenously for patients with chronic inflammatory demyelinating polyneuropathy (CIDP). 

     IV Administration
    Dose

    Induction dose is 2 g/kg in divided doses over 2 to 5 consecutive days, followed by maintenance infusions.


    Maintenance dose is 1 g/kg in divided doses over 1 to 4 consecutive days, every 3 weeks.


    Maintenance dose level and dosing interval of GAMMAGARD LIQUID treatment may be adjusted according to the clinical response.

    Initial Infusion Rate0.5 mL/kg/hr (0.8 mg/kg/min)
    Maintenance Infusion RateInfusion rate may be increased if tolerated up to 5.4 mL/kg/hr (9 mg/kg/min)

    Additional Considerations1

    Ensure patients with preexisting renal insufficiency are not volume depleted; discontinue GAMMAGARD LIQUID if renal function deteriorates. 

    For patients over 65 years of age or judged to be at risk for renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable. 

    Infusion bag icon.

    For patients with CIDP, GAMMAGARD LIQUID IV is given by a healthcare professional. It can be administered at1

    • A patient’s home
    • A physician’s office
    • A hospital
    • An infusion center
    Test tube icon.

    How is GAMMAGARD LIQUID manufactured? 

    Every step of the process ensures reliable, well-controlled, and high safety margins.

    How is GAMMAGARD LIQUID manufactured?

    Reference:

    1. GAMMAGARD LIQUID. Prescribing Information. Takeda Pharmaceuticals U.S.A, Inc.; 2024.